Tandem Diabetes Care and Dexcom Expand Development and Commercialization Agreement to Include Recently Approved G4™ PLATINUM CGM Sensor
SAN DIEGO, CA, January 08, 2013
Tandem Diabetes Care, Inc. (“Tandem”) announced today that its Development and Commercialization Agreement with Dexcom, Inc., has been expanded to include Dexcom’s newest continuous glucose monitoring system, the G4™ PLATINUM. Dexcom announced in October that the G4 PLATINUM was approved by the U.S. Food and Drug Administration (FDA).
“Dexcom’s G4 PLATINUM sensor is the most accurate and easiest to use technology available, and fits well with our product development plans,” said Kim Blickenstaff, President and Chief Executive Officer of Tandem. “Integration of continuous glucose monitoring functionality is a primary focus at Tandem, and something we intend to deliver.”
According to clinical trials conducted by Dexcom, the G4 PLATINUM has improved overall accuracy and ease of use compared to the company’s previous Seven Plus CGM.
The Development and Commercialization Agreement between Tandem and Dexcom is non-exclusive and limited to the U.S. market.
About Dexcom, Inc.
Dexcom, Inc. (www.dexcom.com), headquartered in San Diego, California, is developing and marketing continuous glucose monitoring systems for ambulatory use by patients and by healthcare providers in the hospital.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a privately held company dedicated to advancing the management of diabetes through novel technologies. The Company offers a comprehensive, user-centric and integrated approach to product design, development, and customer care. Tandem Diabetes Care is based in San Diego, Calif.
Follow Tandem Diabetes Care on Twitter @tandemdiabetes, use #tslim.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
t:slim and Tandem Diabetes Care are registered trademarks of Tandem Diabetes Care, Inc.
Dexcom is a registered trademark and Dexcom G4 PLATINUM is a trademark of Dexcom, Inc.